R&D Pipeline

SND001 Linaprazan Glurate capsules

SND001 Linaprazan Glurate(X842) is a next-generation acid-suppressing drug with a novel mechanism, classified as a potassium-ion competitive acid blocker (P-CAB). It works by competitively inhibiting the activity of potassium ions in the H+,K+-ATPase enzyme, thereby effectively suppressing gastric acid secretion. Compared to traditional proton pump inhibitors (PPIs), SND001 boasts rapid onset, prolonged efficacy, and reversible inhibition of the H+,K+-ATPase enzyme. It is indicated for the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter pylori (H. pylori) infection.

SND002 Sentinel Lymph Node T-cell Therapy

SND002, the Sentinel Lymph Node T Cell (SLN-T) anti-tumor drug, is an individually tailored cellular therapy with tumor-specific targeting capabilities, independently developed by Sinorda. SND002 boasts globally independent intellectual property rights and has received approval for a Phase II clinical trial in the European Union, as well as support from China’s National Key Science and Technology Project on "Major New Drug Development." Currently, the company is advancing clinical study applications in both China and Europe. The sentinel lymph node (SLN) serves as the site where T cells undergo "priming," harboring a rich population of non-exhausted, tumor-specific T cells. After ex vivo activation and expansion, these cells are reintroduced into the patient’s body, enabling them to exert highly specific anti-tumor functions. This innovative approach is designed to treat advanced-stage malignant solid tumors. The project achieved proof of concept for SLN-T therapy in its early stage at Karolinska Institute in Sweden, followed by optimization and process development completed in China. To date, nearly 300 exploratory clinical trials have been conducted in both China and Europe, revealing that SLN-T cells can significantly improve survival rates among patients with advanced solid tumors.

SND006 Bispecific Antibody

SND006 is an internationally leading bispecific antibody drug for autoimmune diseases currently being developed by Sinorda Pharma, with inflammatory bowel disease (IBD) as its first targeted indication. To date, the company has successfully completed in vitro functional validation studies of this bispecific antibody, and the candidate antibody molecule has demonstrated superior performance compared to positive-control therapeutic antibodies. SND006 is expected to file an Investigational New Drug (IND) application in 2026. With its novel target combination and broad potential applicability, SND006 holds significant commercial value and is poised to deliver breakthroughs in the treatment of multiple autoimmune disorders.